{
    "data": [
        {
            "title": "BIGLARI HOLDINGS INC. NEWS RELEASE",
            "description": "<div class=\"mdc-article-body\">\n            \n              \n              BIGLARI HOLDINGS INC. NEWS RELEASE\n              \n            \n            \n              <span>\n<h2 class=\"mdc-article-heading mdc-heading__mdc mdc-heading--level-5__mdc\" data-v-618d53ae=\"\">BIGLARI HOLDINGS INC. NEWS RELEASE</h2>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">San Antonio, TX, Feb. 28, 2026</p>\n</span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">San Antonio, TX, <span data-v-602de5d2=\"\">Feb. 28, 2026</span> /PRNewswire/ -- Biglari Holdings Inc.'s (NYSE: BH.A; BH) 2025 Annual Report to the shareholders has been posed on the Internet, where it can be accessed at <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629798-1&amp;h=1720557405&amp;u=http%3A%2F%2Fwww.biglariholdings.com%2F&amp;a=www.biglariholdings.com\" tabindex=\"0\">www.biglariholdings.com</a>. The report includes Sardar Biglari's <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629798-1&amp;h=3311827586&amp;u=http%3A%2F%2Fwww.biglariholdings.com%2Fletters%2F2025%2F2025.pdf&amp;a=annual+letter+to+shareholders\" tabindex=\"0\">annual letter to shareholders</a>.</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Biglari Holdings Inc.'s earnings for the fourth quarter and full year of 2025 and 2024 are summarized below.  To become fully apprised of our results, shareholders should carefully study our 10-K, which has been posted at <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629798-1&amp;h=1531751107&amp;u=https%3A%2F%2Fbiglariholdings.com%2F&amp;a=www.biglariholdings.com\" tabindex=\"0\">www.biglariholdings.com</a>. </p><span><table class=\"mdc-article-table mds-data-table mds-data-table--large\" data-v-0db7e951=\"\"><tbody class=\"mdc-article-table-body mds-data-table__body\"><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(dollars in thousands)</em></span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Fourth Quarter</strong></span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Year Ended December 31,</strong></span></p></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">2025</strong></span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">2024</strong></span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">2025</strong></span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">2024</strong></span></p></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">Pre-tax operating earnings</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$      (1,739)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$        3,896</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$      18,782</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$      32,569</span></p></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">Investment gains (losses)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">(62,319)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">(21,856)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">(66,473)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">(40,723)</span></p></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">Income taxes</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">14,205</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">7,687</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">10,203</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">4,395</span></p></td></tr><tr class=\"mdc-article-table-row mds-data-table__row\"><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">Net earnings (loss)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$    (49,853)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$    (10,273)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$    (37,488)</span></p></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><br/></td><td class=\"mdc-article-table-cell mds-data-table__cell\"><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">$      (3,759)</span></p></td></tr></tbody></table></span><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Analysis of Results</strong>:</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Investments affect our reported quarterly earnings based on their carrying value. We do not regard the quarterly or annual fluctuations in our investments to be meaningful. Therefore, our operating businesses are best analyzed before the impact of investment gains. As a consequence, in the preceding table we separate earnings of our operating businesses from our investment gains.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">At December 31, 2025, our book value per Class A Equivalent share was $2,059.32. (Class B shares have 1/5<span data-v-602de5d2=\"\">th</span> the economic rights of Class A shares.)</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">About Biglari Holdings Inc.</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Biglari Holdings Inc. is a holding company owning subsidiaries engaged in a number of diverse business activities, including property and casualty insurance and reinsurance, licensing and media, restaurants, and oil and gas.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Comment on Regulation G </strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">This press release contains certain non-GAAP financial measures. In addition to the GAAP presentations of net earnings, Biglari Holdings defines pre-tax operating earnings outside of the investment gains/losses of the Company.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Risks Associated with Forward-Looking Statements</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">This news release may include \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ markedly from those projected or discussed here. Biglari Holdings cautions readers not to place undue reliance upon any such forward-looking statements, for actual results may differ materially from expectations. Biglari Holdings does not update publicly or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. Further information on the types of factors that could affect Biglari Holdings and its business can be found in the Company's filings with the SEC.</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img mdc-article-image__img--12-width\" data-v-f0ef0696=\"\" style=\"width:12px;\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://edge.prnewswire.com/c/img/favicon.png?sn=DE98348&amp;sd=2026-02-28\"/></picture></span> View original content:<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://www.prnewswire.com/news-releases/biglari-holdings-inc-news-release-302700189.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/biglari-holdings-inc-news-release-302700189.html</a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">SOURCE Biglari Holdings Inc.</p></span>\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://rt.prnewswire.com/rt.gif?NewsItemId=DE98348&amp;Transmission_Id=202602280944PR_NEWS_USPR_____DE98348&amp;DateId=20260228\"/></picture></span>\n</div>",
            "pub_date": "2026-02-28 23:01:33",
            "link": "https://www.morningstar.com/news/pr-newswire/20260228de98348/biglari-holdings-inc-news-release",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis",
            "description": "<div class=\"mdc-article-body\">\n            \n              \n              Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis\n              \n            \n            \n              <span>\n<h2 class=\"mdc-article-heading mdc-heading__mdc mdc-heading--level-5__mdc\" data-v-618d53ae=\"\">Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis</h2>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">CAMBRIDGE, Mass., Feb. 28, 2026</p>\n</span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">-- Real-world study of AYVAKIT highlights improvement across ISM symptoms --</em></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">-- 12 data presentations at 2026 AAAAI Annual Meeting reflect company's leadership in elevating SM care --</em></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">CAMBRIDGE, Mass.</span>, <span data-v-602de5d2=\"\">Feb. 28, 2026</span> /PRNewswire/ -- Blueprint Medicines, a Sanofi company, today announced AYVAKIT<span data-v-602de5d2=\"\">®</span> (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent systemic mastocytosis (ISM). Key presentations include four-year PIONEER clinical study results highlighting sustained symptom control and quality of life improvement in AYVAKIT-treated patients, and real-world data showing meaningful symptom benefit in patients receiving the therapy in a community practice setting. In addition, a study conducted with the Advanced Practitioner Society for Hematology and Oncology (APSHO) and The Mast Cell Disease Society (TMS) reinforces the severe symptoms and impaired quality of life experienced by patients with ISM. In total, 12 data presentations are being reported at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, February 27 – March 2 in Philadelphia.</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://mma.prnewswire.com/media/2700885/Blueprint_Medicines_a_Sanofi_company_Logo_v2.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/2700885/Blueprint_Medicines_a_Sanofi_company_Logo_v2.jpg\"/></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\"Patients with indolent systemic mastocytosis and healthcare providers have expressed the need for a therapy that meaningfully improves quality of life through durable symptom benefit and a safety profile enabling long-term treatment, and AYVAKIT is delivering this significant impact to a wide range of people living with the disease,\" said Mik Rinne, M.D., Ph.D., Head of Development at Blueprint Medicines. \"Across clinical and real-world settings, AYVAKIT has shown robust efficacy and a well-tolerated safety profile, helping patients realize the sustained benefit of KIT D816V-targeted therapy. In addition, emerging evidence continues to underscore the substantial burden of SM, highlighting the urgency to treat the underlying cause of the disease.\"</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">PIONEER: Long-Term Data Reinforce AYVAKIT as Durable Standard of Care in ISM <br data-v-479a2324=\"\"/></strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Abstracts </strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">509, 518, 530</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-7b473e83=\"\"><li data-v-7b473e83=\"\">Patients showed continued improvement through four years in overall symptoms, all symptom domains (skin, gastrointestinal [GI], neurocognitive) and most severe symptom per the ISM Symptom Assessment Form (ISM-SAF), and quality of life per the Mastocytosis Quality of Life Questionnaire (MC-QoL).</li><li data-v-7b473e83=\"\">In patients with frequent episodes of diarrhea at baseline and at least four years of AYVAKIT (n=44), the median reduction in diarrhea frequency was 65.6 percent. In the overall clinical study population, individual GI symptoms meaningfully improved, allowing for decreased use of cromolyn sodium and other supportive care medicines.</li><li data-v-7b473e83=\"\">Patients had increased bone mineral density – a clinical measure of disease-modifying effects – in the lumbar spine, left total hip and left femoral neck after three years of AYVAKIT. In PIONEER, the change in bone mineral density was assessed in patients who received dual-energy X-ray absorptiometry (DXA) scans (n=79).</li><li data-v-7b473e83=\"\">With a median patient follow-up of about four years (46.5 months; N=226), the safety of AYVAKIT was consistent with the 24-week placebo-controlled portion of the clinical study, and the discontinuation rate due to treatment-related adverse events (TRAEs) was 3 percent (n=6). The majority of edema events, the most common TRAEs, were mild (Grade 1).</li></ul><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Real-World Evidence Further Validates Clinical Benefit of AYVAKIT in ISM<br data-v-479a2324=\"\"/></strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Abstracts 516, 529 </strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-7b473e83=\"\"><li data-v-7b473e83=\"\">A retrospective review of electronic medical records was conducted at ONCare Alliance, a network of community oncology practices, to assess the impact of AYVAKIT in the real-world setting. Median follow-up was 14.2 months.</li><li data-v-7b473e83=\"\">In AYVAKIT-treated patients (N=18), the median time to symptom improvement was rapid (36.5 days). Benefits were frequently reported across a range of symptoms, including GI, skin, abdominal pain and headache symptoms.</li><li data-v-7b473e83=\"\">Among patients who initiated the 25 mg daily dose of AYVAKIT (n=16), 87.5 percent have remained on therapy, reflecting a well-tolerated safety profile.</li><li data-v-7b473e83=\"\">An additional presentation features a systematic literature review of AYVAKIT data, including results from the real-world AVATAR study in patients with uncontrolled ISM (N=17). In this study, the median MC-QoL score decreased from 61 (baseline) to 17 (24 weeks), representing a 76 percent improvement.</li></ul><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Lack of Disease Control and Substantial Burden in Patients with ISM <br data-v-479a2324=\"\"/></strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Abstract 514</strong></p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-7b473e83=\"\"><li data-v-7b473e83=\"\">In collaboration with APSHO and TMS, a survey was developed to identify factors affecting perceptions of disease control in patients with ISM (N=53).</li><li data-v-7b473e83=\"\">Three-quarters of patients (75 percent; n=40) reported that their disease was not optimally controlled.</li><li data-v-7b473e83=\"\">Patients reported severe symptoms regardless of their perceived disease control, underscoring the significant burden across the spectrum of ISM.</li></ul><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Copies of the AAAAI poster presentations are available in the \"Science—Publications and Presentations\" section of Blueprint Medicines' website, <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=3328637867&amp;u=http%3A%2F%2Fwww.blueprintmedicines.com%2F&amp;a=www.blueprintmedicines.com\" tabindex=\"0\">www.blueprintmedicines.com</a>.</p><ul class=\"mdc-article-list mdc-article-list--unordered\" data-v-7b473e83=\"\"><li data-v-7b473e83=\"\">Avapritinib Continues to Demonstrate Durable Symptom Control with a Well-Tolerated Safety Profile: Long-Term Outcomes from PIONEER <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 509 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Real-World Experience of Patients with Indolent Systemic Mastocytosis Treated with Avapritinib in a Community Oncology Setting <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 516 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Avapritinib Durably Improves Gastrointestinal Symptoms of Indolent Systemic Mastocytosis: Long-Term Outcomes from the PIONEER Study <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 518 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Long-Term Bone Health Outcomes in Patients Treated with Avapritinib for Indolent Systemic Mastocytosis: Findings from the PIONEER Study <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 530 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">A Systematic Literature Review of Avapritinib Outcomes in Indolent Systemic Mastocytosis (ISM) Patients <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 529 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Understanding Disease Control: What Shapes Patient Experience in Indolent Systemic Mastocytosis <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 514 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">When One Is Diagnosed, Two Are Changed: The Caregiver Experience in Indolent Systemic Mastocytosis <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 513 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Systemic Mastocytosis: Five-Year Mortality Comparison with Matched Reference Cohorts <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 533 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Mortality Risk by Subtype in Systemic Mastocytosis: A Retrospective Cohort Analysis <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 522 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Ultra-Sensitive SuperRCA Assay Enhances the Ability to Detect KIT D816V Mutations in Peripheral Blood with a Sensitivity Comparable to That of Bone Marrow Testing <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 524 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Are Tryptase Thresholds for Systemic Mastocytosis Adequate? Electronic Health Record (EHR) Data Weigh In <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 527 – Saturday, February 28)</em></li><li data-v-7b473e83=\"\">Project BEACON: Developing a Predictive Model to Accelerate Diagnosis of Indolent Systemic Mastocytosis <em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">(Abstract 517 – Saturday, February 28)</em></li></ul><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">About Systemic Mastocytosis</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). Despite treatment with multiple symptom-directed therapies, patients with ISM frequently experience persistent symptoms including anaphylaxis, maculopapular rash, pruritus, diarrhea, brain fog, fatigue and bone pain, as well as long-term health complications such as osteoporosis. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. There were no approved therapies for ISM until 2023, when AYVAKIT received U.S. Food and Drug Administration (FDA) approval for this indication.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration – including bone lesions, malabsorption, liver dysfunction and bone marrow failure – as well as poor overall survival.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">About Blueprint Medicines' Clinical Studies in SM</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Blueprint Medicines has pursued a broad development program for patients living with SM, including three registrational clinical studies for AYVAKIT and one for elenestinib. PIONEER is a randomized, double-blind, placebo-controlled clinical study designed to assess the safety and efficacy of AYVAKIT in patients with ISM, and PATHFINDER and EXPLORER are open-label, single-arm clinical studies designed to evaluate the safety and efficacy of AYVAKIT in patients with advanced SM.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">The HARBOR clinical study (NCT04910685) of elenestinib, an investigational next-generation KIT D816V inhibitor, is currently enrolling patients with ISM. HARBOR is a randomized, double-blind, placebo-controlled clinical study that includes dose-finding Part 1, registrational Part 2 and long-term treatment Part 3. All patients who complete Parts 1 or 2 have an opportunity to receive treatment with elenestinib in Part 3. Key endpoints include changes in patient-reported symptoms, biomarkers and bone mineral density, annualized rate of anaphylaxis events, and safety.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Patients and clinicians interested in the ongoing HARBOR clinical study can contact Blueprint Medicines at <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"mailto:medinfo@blueprintmedicines.com\" tabindex=\"0\">medinfo@blueprintmedicines.com</a> or +1 (617) 714-6707. Additional details are available at <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=520014390&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04910685&amp;a=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04910685\" tabindex=\"0\">https://clinicaltrials.gov/study/NCT04910685</a> or <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=3205934362&amp;u=https%3A%2F%2Fharborclinicaltrial.com%2F&amp;a=https%3A%2F%2Fharborclinicaltrial.com\" tabindex=\"0\">https://harborclinicaltrial.com</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">About AYVAKIT</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">AYVAKIT (avapritinib) is the first and only medicine approved by the FDA to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and ISM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including ASM, SM-AHN and MCL, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as AYVAKYT<span data-v-602de5d2=\"\">®</span> for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. The therapy is not recommended for the treatment of patients with low platelet counts (less than 50,000/µL). Globally, the medicine is approved for one or more indications in more than 35 countries worldwide, including China where it has been developed and commercialized by CStone Pharmaceuticals, which pays tiered percentage royalties on sales.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Please click here to see the full <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=2128645761&amp;u=https%3A%2F%2Fwww.blueprintmedicines.com%2Fwp-content%2Fuploads%2Fuspi%2FAYVAKIT.pdf&amp;a=U.S.%C2%A0Prescribing+Information\" tabindex=\"0\">U.S. Prescribing Information</a> for AYVAKIT, and click here to see the <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=1049365237&amp;u=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Fayvakyt-epar-product-information_en.pdf&amp;a=European+Summary+of+Product+Characteristics\" tabindex=\"0\">European Summary of Product Characteristics</a> for AYVAKYT.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Important Safety Information</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Cognitive Effects — Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC; &lt;1% were Grade 3. Depending on the severity, withhold AYVAKIT and then resume at the same dose, or permanently discontinue AYVAKIT.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Photosensitivity — AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Embryo-Fetal Toxicity — AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Adverse Reactions — The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors or inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or visit <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=2571560791&amp;u=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;a=www.fda.gov%2Fmedwatch\" tabindex=\"0\">www.fda.gov/medwatch</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Please click here to see the full <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=2128645761&amp;u=https%3A%2F%2Fwww.blueprintmedicines.com%2Fwp-content%2Fuploads%2Fuspi%2FAYVAKIT.pdf&amp;a=U.S.%C2%A0Prescribing+Information\" tabindex=\"0\">U.S. Prescribing Information</a> for AYVAKIT.</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">About Blueprint Medicines, a Sanofi Company </strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Blueprint Medicines, a Sanofi company, seeks to alleviate human suffering by solving important medical problems in allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, leveraging deep expertise in our core focus areas. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe, and we aim to scale our impact by advancing programs in mast cell diseases and solid tumors. For more information, visit <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=3328637867&amp;u=http%3A%2F%2Fwww.blueprintmedicines.com%2F&amp;a=www.blueprintmedicines.com\" tabindex=\"0\">www.blueprintmedicines.com</a> and follow us on <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=2129716581&amp;u=https%3A%2F%2Fx.com%2Fblueprintmeds&amp;a=X\" tabindex=\"0\">X</a> (formerly Twitter; @BlueprintMeds) and <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629544-1&amp;h=3557225347&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fblueprint-medicines%2F&amp;a=LinkedIn\" tabindex=\"0\">LinkedIn</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Trademarks</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img mdc-article-image__img--12-width\" data-v-f0ef0696=\"\" style=\"width:12px;\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://edge.prnewswire.com/c/img/favicon.png?sn=NE98092&amp;sd=2026-02-28\"/></picture></span> View original content to download multimedia:<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://www.prnewswire.com/news-releases/blueprint-medicines-a-sanofi-company-announces-four-year-pioneer-data-showing-sustained-benefit-and-long-term-safety-of-ayvakit-avapritinib-in-indolent-systemic-mastocytosis-302700182.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/blueprint-medicines-a-sanofi-company-announces-four-year-pioneer-data-showing-sustained-benefit-and-long-term-safety-of-ayvakit-avapritinib-in-indolent-systemic-mastocytosis-302700182.html</a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">SOURCE Blueprint Medicines, a Sanofi company</p></span>\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://rt.prnewswire.com/rt.gif?NewsItemId=NE98092&amp;Transmission_Id=202602280945PR_NEWS_USPR_____NE98092&amp;DateId=20260228\"/></picture></span>\n</div>",
            "pub_date": "2026-02-28 23:01:33",
            "link": "https://www.morningstar.com/news/pr-newswire/20260228ne98092/blueprint-medicines-a-sanofi-company-announces-four-year-pioneer-data-showing-sustained-benefit-and-long-term-safety-of-ayvakit-avapritinib-in-indolent-systemic-mastocytosis",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SDM Deadline: SDM Investors with Losses in Excess of $100K Have Opportunity to Lead Smart Digital Group Ltd. Securities Fraud Lawsuit",
            "description": "<div class=\"mdc-article-body\">\n            \n              \n              SDM Deadline: SDM Investors with Losses in Excess of $100K Have Opportunity to Lead Smart Digital Group Ltd. Securities Fraud Lawsuit\n              \n            \n            \n              <span>\n<h2 class=\"mdc-article-heading mdc-heading__mdc mdc-heading--level-5__mdc\" data-v-618d53ae=\"\">SDM Deadline: SDM Investors with Losses in Excess of $100K Have Opportunity to Lead Smart Digital Group Ltd. Securities Fraud Lawsuit</h2>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">NEW YORK, Feb. 28, 2026</p>\n</span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">NEW YORK</span>, <span data-v-602de5d2=\"\">Feb. 28, 2026</span> /PRNewswire/ --</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg\"/></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Smart Digital Group Ltd. (NASDAQ: SDM) between May 5, 2025 and September 26, 2025 at 9:34 AM EST, both dates inclusive (the \"Class Period\"), of the important March 16, 2026 lead plaintiff deadline.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">So what: If you purchased SDM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">What to do next: To join the SDM class action, go to <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=2535422655&amp;u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D50638&amp;a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D50638\" tabindex=\"0\">https://rosenlegal.com/submit-form/?case_id=50638</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"mailto:case@rosenlegal.com\" tabindex=\"0\">case@rosenlegal.com</a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Smart Digital was the subject of a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals; (2) insiders and/or affiliates used and/or intended to use offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Smart Digital's public statements and risk disclosures omitted any mention of realized risk of fraudulent trading or market manipulation used to drive Smart Digital's stock price; (4) as a result, Smart Digital securities were at unique risk of a sustained suspension in trading by either or both of the SEC and NASDAQ; and (5) as a result of the foregoing, defendants' positive statements about Smart Digital's business, operations and prospects were materially misleading and/or lacked a reasonable basis.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">To join the SDM class action, go to <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=2535422655&amp;u=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D50638&amp;a=https%3A%2F%2Frosenlegal.com%2Fsubmit-form%2F%3Fcase_id%3D50638\" tabindex=\"0\">https://rosenlegal.com/submit-form/?case_id=50638</a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"mailto:case@rosenlegal.com\" tabindex=\"0\">case@rosenlegal.com</a> for information on the class action.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Follow us for updates on LinkedIn: <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=701037670&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm\" tabindex=\"0\">https://www.linkedin.com/company/the-rosen-law-firm</a>, on Twitter: <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=330085938&amp;u=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;a=https%3A%2F%2Ftwitter.com%2Frosen_firm\" tabindex=\"0\">https://twitter.com/rosen_firm</a> or on Facebook: <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=3817979679&amp;u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F\" tabindex=\"0\">https://www.facebook.com/rosenlawfirm/</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Attorney Advertising. Prior results do not guarantee a similar outcome.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Contact Information:</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">      Laurence Rosen, Esq.<br data-v-602de5d2=\"\"/>      Phillip Kim, Esq.<br data-v-602de5d2=\"\"/>      The Rosen Law Firm, P.A.<br data-v-602de5d2=\"\"/>      275 Madison Avenue, 40th Floor<br data-v-602de5d2=\"\"/>      New York, NY 10016<br data-v-602de5d2=\"\"/>      Tel: (212) 686-1060<br data-v-602de5d2=\"\"/>      Toll Free: (866) 767-3653<br data-v-602de5d2=\"\"/>      Fax: (212) 202-3827<br data-v-602de5d2=\"\"/>      <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"mailto:case@rosenlegal.com\" tabindex=\"0\">case@rosenlegal.com</a><br data-v-602de5d2=\"\"/>      <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629730-1&amp;h=2118701566&amp;u=http%3A%2F%2Fwww.rosenlegal.com%2F&amp;a=www.rosenlegal.com\" tabindex=\"0\">www.rosenlegal.com</a></p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img mdc-article-image__img--12-width\" data-v-f0ef0696=\"\" style=\"width:12px;\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://edge.prnewswire.com/c/img/favicon.png?sn=DC98281&amp;sd=2026-02-28\"/></picture></span> View original content to download multimedia:<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://www.prnewswire.com/news-releases/sdm-deadline-sdm-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-smart-digital-group-ltd-securities-fraud-lawsuit-302700065.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/sdm-deadline-sdm-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-smart-digital-group-ltd-securities-fraud-lawsuit-302700065.html</a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">SOURCE THE ROSEN LAW FIRM, P. A.</p></span>\n</div>",
            "pub_date": "2026-02-28 22:46:39",
            "link": "https://www.morningstar.com/news/pr-newswire/20260228dc98281/sdm-deadline-sdm-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-smart-digital-group-ltd-securities-fraud-lawsuit",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Trump blacklists Anthropic - and OpenAI swoops in",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  By William Gavin </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Claude developer Anthropic refused to let its products be deployed for autonomous weapons or mass surveillance </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Anthropic CEO Dario Amodei has warned that artificial intelligence has the capabilities to undermine democratic values. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     President Donald Trump on Friday ordered the U.S. government to stop using Anthropic's artificial-intelligence models and threatened the company with \"major\" consequences. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"Anthropic better get their act together, and be helpful during this phase out period, or I will use the Full Power of the Presidency to make them comply, with major civil and criminal consequences to follow,\" Trump said in a post on his Truth Social platform. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Trump directed all federal agencies to immediately stop using Anthropic's Claude AI models. He added that the Department of Defense and other U.S. agencies have six months to phase out Anthropic's technology. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The conflict stems from Anthropic's contract with the Defense Department, which is worth up to $200 million. Anthropic has drawn a line in the sand over how the department can use its technology. Specifically, Anthropic doesn't want its products to be used to develop autonomous weapons or for mass surveillance. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Pentagon has said it has \"no interest\" in using AI for those purposes. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     But something curious happened after Trump's announcement about Anthropic: OpenAI said that it had struck a government deal and that it was able to secure carve-outs. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"Two of our most important safety principles are prohibitions on domestic mass surveillance and human responsibility for the use of force, including for autonomous weapon systems,\" OpenAI CEO Sam Altman said on the X platform. The Defense Department \"agrees with these principles, reflects them in law and policy, and we put them into our agreement,\" he added. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Meanwhile, Anthropic CEO Dario Amodei said in a blog post that his company \"tried in good faith to reach an agreement with the Department of War,\" using the name the Trump administration prefers for the Pentagon, \"making clear that we support all lawful uses of AI for national security aside from the two narrow exceptions.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The company does \"not believe that today's frontier AI models are reliable enough to be used in fully autonomous weapons,\" he added. And, he said, the team at Anthropic believes \"that mass domestic surveillance of Americans constitutes a violation of fundamental rights.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Trump's announcement came after days of public and private back-and-forth negotiations between the Pentagon and Anthropic that occasionally turned ugly. After Amodei defended his company's refusal to budge on Thursday, a Pentagon official accused him of trying to \"personally control the U.S. military.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"It's a shame that @DarioAmodei is a liar and has a God-complex,\" Emil Michael, the undersecretary of defense for research and engineering, wrote on X. Michael, a former executive at Uber Technologies (UBER), also accused Anthropic of having a plan to \"impose\" its values on Americans. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     A Jan. 9 memo handed down by Defense Secretary Pete Hegseth called for AI labs to amend their defense contracts to allow \"any lawful use\" of their technology. Hegseth gave the department 180 days to insert that standard into any contract that involves procuring AI services. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"DoD does not want a private company's usage policy to function as a veto over lawful military applications,\" Jessica Tillipman, a professor at George Washington University's law school who specializes in government procurement law, told MarketWatch over email. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"If DoD makes this the default clause across all AI vendors, it eliminates vendor-by-vendor negotiation over acceptable use and signals that firms unwilling to accept that baseline will be replaced,\" Tillipman said. \"It sounds like boring contract boilerplate, but it is really about procurement leverage.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Following Trump's announcement, Hegseth formally declared Anthropic a supply-chain risk to national security, a designation previously applied only to foreign companies, notably those based in China and believed to be under government influence. As a result of Hegseth's action, no contractor, supplier or partner that does business with the U.S. military can conduct \"any commercial activity\" with Anthropic. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     That has potentially major implications for Anthropic, which recently raised $30 billion at a $380 billion valuation and disclosed $14 billion in annual run-rate revenue, driven mostly by increasing enterprise adoption of its products. More than 500 business customers now spend over $1 million annually on Anthropic's products. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Microsoft (MSFT), which alongside Nvidia (NVDA) signed a strategic partnership with Anthropic last November, works with the Defense Department.  Amazon (AMZN), which has invested billions of dollars in Anthropic, recently detailed a plan to support the Pentagon through access to Amazon Web Services. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Before this week, Claude was the only AI model approved for classified use in the Pentagon. Claude was even used, through a Palantir Technologies (PLTR) partnership, to help the U.S. capture Venezuela's then-president, Nicolás Maduro, according to the Wall Street Journal. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     However, Elon Musk's xAI signed a deal to allow its controversial Grok model to be used for classified purposes earlier this week. Officials at multiple federal agencies have raised concerns over potential safety issues with Grok, the Journal reports. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     See: Amazon, Nvidia and SoftBank pour $110 billion into OpenAI - raising the stakes for AI monetization </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Emily Bary contributed. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     -William Gavin </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-370ea3ac=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  02-28-26 0942ET</p>\n\nCopyright (c) 2026 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2026-02-28 22:46:38",
            "link": "https://www.morningstar.com/news/marketwatch/20260228157/trump-blacklists-anthropic-and-openai-swoops-in",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Any chance of a Fed interest-rate cut in 2026 is 'evaporating before our very eyes' with Iran war set to stoke oil prices",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  By Greg Robb </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     U.S. and Israel strike several locations in Iran, which responds with missile attacks on Gulf nations </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     President Donald Trump greeted members of the Joint Chiefs of Staff as he arrived to deliver his State of the Union address on Tuesday. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     War with Iran is expected to lead to a spike in oil prices, which, if prolonged, could mean the next move by the Federal Reserve is to raise interest rates. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     President Donald Trump has called for regime change in Iran. Experts said one of the largest-scale concerns is that this Iranian regime will see its very existence at stake. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Iranian regime \"is going to do whatever they can and whatever they believe will help them stay in power,\" said Suzanne Maloney, director of the foreign-policy program at the Brookings Institution, speaking at a Chicago Council on Global Affairs event this week. \"That does include striking both their neighbors, against energy infrastructure in the region, and, of course, against Israel and the U.S. military and any other presence in the region. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"It could be a very dangerous time in the aftermath of American military action in Iran.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     For the U.S. economy, meanwhile, it seems certain that war will push the inflation rate higher. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"The argument for having lower rates is just evaporating right before our very eyes,\" said Brian Bethune, an economist at Boston College, in an interview with MarketWatch. The uptick in oil prices combined with the Trump administration's aggressive approach to tariffs will keep prices high. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     See: After the U.S. and Israel attack Iran, bitcoin and oil are offering glimpses into the broader response of markets </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Over the past several months, the Fed has struggled to tamp down inflation amid pressure from the White House and the markets to cut rates. These latest developments in the Middle East only add to the central bank's challenges. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Prices at the wholesale level started to accelerate in December and are now running at a 3% annual rate, frustrating Federal Reserve officials who had hoped that Trump's new levies on imports would have only a transitory impact on inflation. It's likely that the increase in producer prices will soon be passed on to consumers, said Ethan Harris, former chief economist at BofA Securities, in a note on LinkedIn. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Inflation is looking like it's heating up in the first quarter, agreed Scott Anderson, chief U.S. economist at BMO Capital Markets. Core personal-consumption expenditures could rise to a 3.1% annual rate in January, the highest rate in two years - and that's before any impact from the strike on Iran and its repercussions. The Fed's annual target for inflation is 2%. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Any $10 increase in crude-oil prices is estimated to raise consumer-price inflation by 0.2% to 0.4% over the coming year, Anderson said. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     WTI crude-oil futures (CL00) (CLJ26) are up about 16% to date in 2026, or $10 per barrel. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices were already rising as tension with Iran was rising, and now a prolonged conflict might raise the possibility that the central bank's next move would be to raise interest rates, Anderson added. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"You're really talking about problems for the Fed in terms of putting a lid on inflation,\" Bethune said. \"In this situation, the Fed can't lower rates.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Traders in derivate markets still expect two quarter-point rate cuts this year, with the first coming in June and the second in September. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Both tariffs and oil prices are supply shocks, raising the costs of inputs into production of the economy, which are very hard for the Fed to cool. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Fed's interest-rate tool kit works more on the demand side of the economy, by either spurring companies and consumers to spend or nudging them to pull back. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices to spike as Iran hits neighbors </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices are expected to spike now that Iran's missiles have hit other Gulf states. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Iran  has the ability to disrupt the flow of oil through the Strait of Hormuz, a crucial maritime passage connecting the Persian Gulf with the Gulf of Oman and the Arabian Sea. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Christopher Granville, managing director of TS Lombard, a macroeconomic forecasting consultancy firm based in London, said a military confrontation between the U.S. and Iran is unlikely to send the global economy into a full-blown oil crisis or stagflationary shock. Still, it's possible we'll face an \"oil squall\" similar to what happened after Russia invaded Ukraine in February 2022, when oil prices surged over $100 a barrel and remained high for six months. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     That so-called squall was enough to fuel inflation in the U.S., with the core PCE price index rising at an annual pace of 5.6% in September 2022, its highest rate in almost 40 years. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Karen Young, senior research scholar at the Center for Global Energy Policy at Columbia University, said any price spike depends on whether the Iranian regime strikes oil-production facilities of its neighbors in the Middle East in response to the U.S.-Israel action. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Vali Nasr, a professor at the Johns Hopkins University's School of Advanced International Studies, had said it was likely that Iran would hit its neighbors. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     For as long as the Iranian regime holds out, said Granville, the \"squall risk\" will persist, pointing to a sticky risk premium in oil prices and, in effect, putting a floor under what would otherwise be fundamentally driven weakness. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     During whatever time span is required for U.S. military power to neutralize Iran's defense capabilities, the oil price spike would endure, but that same \"whatever it takes\" response, according to Granville, would prevent any Iranian action setting ablaze the whole of the Gulf and precipitating a full-blown, 1970s-style oil crisis. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     -Greg Robb </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-370ea3ac=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  02-28-26 0922ET</p>\n\nCopyright (c) 2026 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2026-02-28 22:36:41",
            "link": "https://www.morningstar.com/news/marketwatch/20260228152/any-chance-of-a-fed-interest-rate-cut-in-2026-is-evaporating-before-our-very-eyes-with-iran-war-set-to-stoke-oil-prices",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Any chance of a Fed interest-rate cut in 2026 is 'evaporating before our very eyes' with Iran war set to stoke oil prices",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  By Greg Robb </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     U.S. and Israel strike several locations in Iran, which responds with missile attacks on Gulf nations </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     President Donald Trump greeted members of the Joint Chiefs of Staff as he arrived to deliver his State of the Union address on Tuesday. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     War with Iran is expected to lead to a spike in oil prices, which, if prolonged, could mean the next move by the Federal Reserve is to raise interest rates. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     President Donald Trump has called for regime change in Iran. Experts said one of the largest-scale concerns is that this Iranian regime will see its very existence at stake. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Iranian regime \"is going to do whatever they can and whatever they believe will help them stay in power,\" said Suzanne Maloney, director of the foreign-policy program at the Brookings Institution, speaking at a Chicago Council on Global Affairs event this week. \"That does include striking both their neighbors, against energy infrastructure in the region, and, of course, against Israel and the U.S. military and any other presence in the region. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"It could be a very dangerous time in the aftermath of American military action in Iran.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     For the U.S. economy, meanwhile, it seems certain that war will push the inflation rate higher. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"The argument for having lower rates is just evaporating right before our very eyes,\" said Brian Bethune, an economist at Boston College, in an interview with MarketWatch. The uptick in oil prices combined with the Trump administration's aggressive approach to tariffs will keep prices high. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     See: After the U.S. and Israel attack Iran, bitcoin and oil are offering glimpses into the broader response of markets </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Over the past several months, the Fed has struggled to tamp down inflation amid pressure from the White House and the markets to cut rates. These latest developments in the Middle East only add to the central bank's challenges. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Prices at the wholesale level started to accelerate in December and are now running at a 3% annual rate, frustrating Federal Reserve officials who had hoped that Trump's new levies on imports would have only a transitory impact on inflation. It's likely that the increase in producer prices will soon be passed on to consumers, said Ethan Harris, former chief economist at BofA Securities, in a note on LinkedIn. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Inflation is looking like it's heating up in the first quarter, agreed Scott Anderson, chief U.S. economist at BMO Capital Markets. Core personal-consumption expenditures could rise to a 3.1% annual rate in January, the highest rate in two years - and that's before any impact from the strike on Iran and its repercussions. The Fed's annual target for inflation is 2%. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Any $10 increase in crude-oil prices is estimated to raise consumer-price inflation by 0.2% to 0.4% over the coming year, Anderson said. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     WTI crude-oil futures (CL00) (CLJ26) are up about 16% to date in 2026, or $10 per barrel. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices were already rising as tension with Iran was rising, and now a prolonged conflict might raise the possibility that the central bank's next move would be to raise interest rates, Anderson added. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"You're really talking about problems for the Fed in terms of putting a lid on inflation,\" Bethune said. \"In this situation, the Fed can't lower rates.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Traders in derivate markets still expect two quarter-point rate cuts this year, with the first coming in June and the second in September. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Both tariffs and oil prices are supply shocks, raising the costs of inputs into production of the economy, which are very hard for the Fed to cool. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Fed's interest-rate tool kit works more on the demand side of the economy, by either spurring companies and consumers to spend or nudging them to pull back. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices to spike as Iran hits neighbors </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Oil prices are expected to spike now that Iran's missiles have hit other Gulf states. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Iran  has the ability to disrupt the flow of oil through the Strait of Hormuz, a crucial maritime passage connecting the Persian Gulf with the Gulf of Oman and the Arabian Sea. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Christopher Granville, managing director of TS Lombard, a macroeconomic forecasting consultancy firm based in London, said a military confrontation between the U.S. and Iran is unlikely to send the global economy into a full-blown oil crisis or stagflationary shock. Still, it's possible we'll face an \"oil squall\" similar to what happened after Russia invaded Ukraine in February 2022, when oil prices surged over $100 a barrel and remained high for six months. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     That so-called squall was enough to fuel inflation in the U.S., with the core PCE price index rising at an annual pace of 5.6% in September 2022, its highest rate in almost 40 years. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Karen Young, senior research scholar at the Center for Global Energy Policy at Columbia University, said any price spike depends on whether the Iranian regime strikes oil-production facilities of its neighbors in the Middle East in response to the U.S.-Israel action. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Vali Nasr, a professor at the Johns Hopkins University's School of Advanced International Studies, had said it was likely that Iran would hit its neighbors. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     -Greg Robb </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-370ea3ac=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  02-28-26 0917ET</p>\n\nCopyright (c) 2026 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2026-02-28 22:25:59",
            "link": "https://www.morningstar.com/news/marketwatch/20260228150/any-chance-of-a-fed-interest-rate-cut-in-2026-is-evaporating-before-our-very-eyes-with-iran-war-set-to-stoke-oil-prices",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan",
            "description": "<div class=\"mdc-article-body\">\n            \n              \n              Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan\n              \n            \n            \n              <span>\n<h2 class=\"mdc-article-heading mdc-heading__mdc mdc-heading--level-5__mdc\" data-v-618d53ae=\"\">Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan</h2>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">BEIJING, Feb. 28, 2026</p>\n</span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">BEIJING</span>, <span data-v-602de5d2=\"\">Feb. 28, 2026</span> /PRNewswire/ -- A news report from China.org.cn on Chinese economy:</p><span><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"> </p></span><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">The year 2026 marks the beginning of China's 15th Five-Year Plan period (2026-2030). To achieve a strong and stable start, China's economy relies on its powerful domestic growth drivers, as well as its unique systematic advantages.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">In today's world, the scarcest resource is the market. China, with its 1.4 billion people and the world's most complete industrial system, is steadily reinforcing its unified national market, catalyzing the country's economic development. In the Yangtze River Delta, a new energy vehicle (NEV) manufacturer can quickly secure all necessary components — from battery materials in Ningde to smart screens in Shanghai — within just four hours. In the Beijing-Tianjin-Hebei region, manufacturing materials can also be swiftly reallocated and dispatched via land ports, despite administrative boundaries. Across China, authorities are accelerating efforts to break down administrative barriers and facilitate the free flow of economic resources, enabling optimal resource allocation for more industries nationwide. The organic integration of the unified national market is a vivid embodiment of China's economic resilience and strength.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">The consumption engine continues to gather momentum, injecting renewed vitality that supports the long-term strength of the Chinese economy. China is home to the world's largest middle-income group and an enormous domestic consumer market with immense potential. In the past year, domestic demand contributed over 67% of China's GDP growth. Buoyed by the consumer goods trade-in program, retail turnover for home appliances and communication devices have both surpassed the one trillion yuan mark. Trendy toy IPs continue to gain traction, micro-dramas have risen rapidly, and a single performance can make an entire city go viral. Such new types of service-oriented consumption centered on new scenarios, business formats and operating models are emerging as potential fresh growth drivers for China's consumption market. As consumption upgrading gathers pace, it is also steadily shouldering the main responsibility for driving China's economic growth.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">More targeted investment is delivering greater efficiency. As one of the three drivers of economic growth, investment in China has shifted from a broad \"flood-style\" approach to targeted measures that aim to bolster weak links. For example, new infrastructure projects like the national computing power hubs have been rolled out and generated tangible results; livelihood-focused investments such as the renovation of old residential communities and the construction of social-security housing have brought warmth to many; investments in manufacturing technological upgrading have consistently improved productivity among traditional industries. By directing investment towards the real economy, improvements to well-being and industry upgrading, China is not only stimulating economic growth in the present, but also building momentum for the long term, ensuring that every yuan invested delivers maximum impact.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">The momentum of technological innovation is picking up pace, becoming a new engine that spurs development. China's core AI industry has exceeded 1 trillion yuan, with \"AI+\" business formats mushrooming in industrial and commercial sectors. China's NEV production and sales have ranked first globally for 11 consecutive years; cutting-edge technologies like gene editing and cell therapy have provided new solutions for treating complex diseases. The new system for mobilizing resources nationwide has helped break through key technological bottlenecks, and fruits of technological innovation are rapidly moving from the lab onto production lines, fueling economic development with a steady surge of new momentum.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">From the scale advantage of a unified national market to the domestic vitality of consumption, and from the effective boost of targeted investments to the core drive of technological innovation, the intrinsic forces propelling China's economy are going from strength to strength, with the country's systematic advantages becoming ever more pronounced. These forces empower one another, creating a powerful synergy that makes a solid start to the 15th Five-Year Plan not only a clear target, but also an inevitable outcome.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan <br data-v-370fea16=\"\"/></em></strong><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><span class=\"mdc-article-underline\" data-v-1f1bdc8a=\"\"><a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"http://www.china.org.cn/video/2026-02/28/content_118351275.shtml\" tabindex=\"0\">http://www.china.org.cn/video/2026-02/28/content_118351275.shtml</a><br data-v-1f1bdc8a=\"\"/></span></em><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\">China Mosaic <br data-v-370fea16=\"\"/></em></strong><span class=\"mdc-article-underline\" data-v-1f1bdc8a=\"\"><em class=\"mdc-article-emphasis\" data-v-370fea16=\"\"><a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"http://chinamosaic.china.com.cn/\" tabindex=\"0\">http://chinamosaic.china.com.cn/</a></em></span></p>\n<span>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img mdc-article-image__img--12-width\" data-v-f0ef0696=\"\" style=\"width:12px;\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://edge.prnewswire.com/c/img/favicon.png?sn=CN98439&amp;sd=2026-02-28\"/></picture></span> View original content to download multimedia:<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://www.prnewswire.com/news-releases/well-grounded-confidence-how-chinas-domestic-growth-drivers-propel-a-strong-start-to-its-15th-five-year-plan-302700154.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/well-grounded-confidence-how-chinas-domestic-growth-drivers-propel-a-strong-start-to-its-15th-five-year-plan-302700154.html</a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">SOURCE China.org.cn</p></span>\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://rt.prnewswire.com/rt.gif?NewsItemId=CN98439&amp;Transmission_Id=202602280900PR_NEWS_USPR_____CN98439&amp;DateId=20260228\"/></picture></span>\n</div>",
            "pub_date": "2026-02-28 22:16:32",
            "link": "https://www.morningstar.com/news/pr-newswire/20260228cn98439/well-grounded-confidence-how-chinas-domestic-growth-drivers-propel-a-strong-start-to-its-15th-five-year-plan",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "My brother is paranoid, alone and has forgotten that he sold his house. How can we help?",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  By Quentin Fottrell </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     His lawyer said, 'He's gone off the deep end' </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"The lawyer's last words to us was we might have to appoint a new executor if his condition continues to deteriorate.\" (Photo subject is a model.) </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Dear Quentin, </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     My sister and I have held power of attorney for my brother, who lives six hours away. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     He has been in an assisted-living facility for over three years. Physically, he is not able to live independently, but was or is pretty sharp mentally. We take care of all his bills; his house and car were sold over three years ago. His wife died in 2020; they had no children. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Over the last 10 days, he started calling my sister about bills he needed to pay; all his bills are being paid by her. He also wants to know the balance in his bank accounts. My sister has always given him this information when he asks. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     He wanted to see the lawyer recently. He was very paranoid, asking staff to witness their conversation. He doesn't remember that he sold his house or car. In an email, his lawyer said, \"He's gone off the deep end.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The lawyer's last words to us were we might have to appoint a new executor if his condition continues to deteriorate. My sister and I are his only family, the will is made and we would inherit his estate. What do we do next? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The Other Sibling </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Don't miss: 'I spend $7,500 a month': I'm 47, earn $260K, and have $3 million. Can I retire at 50? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     You can email The Moneyist with any financial and ethical questions at qfottrell@marketwatch.com. The Moneyist regrets he cannot reply to questions individually. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     A durable power of attorney would continue to carry out these duties after if/when your brother becomes incapacitated. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Dear Sibling, </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     I'm not encouraged by the tone or content of his attorney's email. It lacks compassion, professionalism and respect. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Your brother is confused and needs help. But he doesn't need an executor. An executor is appointed by the probate court after your brother passes away (and would typically be designated executor in his will). A power of attorney usually looks after a person's finances while they have diminished capacity; a durable power of attorney would continue to carry out these duties after if/when your brother becomes incapacitated. A conservator/guardian would be appointed by the courts to oversee his financial, physical and medical wellbeing. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Take immediate steps to safeguard your brother's safety: He may need an assessment for dementia or cognitive impairment from a neurologist or geriatrician. I hope that the assisted-living facility is aware of this change of behavior, and is equipped to help him navigate this next stage. You will all need to work together until you figure out the next steps for your brother. Questions remain: What kind of power of attorney document currently exists? What legal capacity does your brother have to make decisions for himself - everything from hiring a new lawyer to revoking a POA? Has your brother been actually diagnosed with dementia? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     A durable power of attorney would continue if/when your brother becomes incapacitated. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Most of all, you will require health advocates and a competent lawyer. If the lawyer mentioned in your letter is not equipped to deal with your brother's situation - and it could be so given his reaction to the decline in your brother's health - you need a new lawyer to oversee your brother's affairs; as his joint powers of attorney, you can help him to appoint one. They will be able to help outline your options, which will depend on what kind of POA you hold and whether or not your brother requires conservatorship/guardianship, which should be a last resort. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Laws regarding a conservator/guardian vary by state. In Texas, you would need to file a petition with the court. \"A hearing will be held, and the judge will examine the evidence and make a decision,\" says Childs Legacy Law Firm in Houston. \"In the second instance, absent a pending petition, and in lieu of a family member, living will or another relevant document, the court will appoint a conservator. The conservator can be any number of people, like a friend, social worker, neighbor, church member, attorney, nurse [or] another qualified person.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     General conservatorship </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"A general conservatorship is created when an adult - typically an elderly person but can be a younger adult person - cannot manage their finances or health due to deteriorated mental capacity or impairment caused by an illness or injury,\" it adds. \"While they recover from the illness or injury, a conservator may be appointed by a court to address their medical and financial needs.\" Reasons include a person falling into a coma, a form of dementia like Alzheimer's, head injury or a stroke that impairs their ability to think or express their wishes. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Your brother's condition appears to be deteriorating, quite suddenly. \"People who suffer from any of the above can become vulnerable to bad actors who may try to manipulate the situation for their own financial gain. These bad actors may, for example, attempt to divert your disability payments (fraud) or coerce you into changing a will (undue influence),\" the law firm says. It is always better to draft an estate plan while you have the legal capacity to write and sign such a document. Otherwise, it will be left up to the courts. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Your brother's condition appears to be deteriorating. He needs calm and legal protection. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Right now, your brother needs reassurance and validation, clear and comforting communication, a routine so he feels safe, and legal protection; document everything, especially his changes in behavior. If he does not already have a healthcare proxy or healthcare power of attorney, and your brother is not of sound mind, the courts will appoint one for him. If he is in assisted living, for example, there may come a time when you will have to move him to a full-time care facility. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     In the absence of long-term-care insurance or Medicaid, I assume you will use (or have used) the proceeds from the sale of his house to pay for his care. Selling a primary residence turns the home's equity from an exempt asset into countable cash, which often exceeds the strict monthly $2,000-$3,000 individual limit for Medicaid, which would lead to a temporary loss of benefits until those funds are spent. A trust and estate attorney can talk through your options. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     You can do this. But you can't - nor should you - do it alone. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Related: 'I am fearful': My ailing relative is being forced into assisted living. What can I do? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     More columns from Quentin Fottrell: </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Can I stop my kids from using their inheritance to support political causes I vehemently oppose? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     My wife's credit-card payment is three months overdue. As an authorized user, am I in trouble? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     My stepmother cheated me out of $500K from my father's estate. What can I do? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Check out The Moneyist's private Facebook group, where members help answer life's thorniest money issues. Post your questions, or weigh in on the latest Moneyist columns. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     By emailing your questions to The Moneyist or posting your dilemmas on The Moneyist Facebook group, you agree to have them published anonymously on MarketWatch. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     By submitting your story to Dow Jones &amp; Co., the publisher of MarketWatch, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     -Quentin Fottrell </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-370ea3ac=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  02-28-26 0903ET</p>\n\nCopyright (c) 2026 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2026-02-28 22:16:31",
            "link": "https://www.morningstar.com/news/marketwatch/20260228148/my-brother-is-paranoid-alone-and-has-forgotten-that-he-sold-his-house-how-can-we-help",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics",
            "description": "<div class=\"mdc-article-body\">\n            \n              \n              AQST INVESTOR NOTICE: Faruqi &amp; Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics\n              \n            \n            \n              <span>\n<h2 class=\"mdc-article-heading mdc-heading__mdc mdc-heading--level-5__mdc\" data-v-618d53ae=\"\">AQST INVESTOR NOTICE: Faruqi &amp; Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics</h2>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">PR Newswire</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">NEW YORK, Feb. 28, 2026</p>\n</span>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Faruqi &amp; Faruqi, LLP Securities Litigation Partner </strong><a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=1653552366&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2Fattorney%2F22%2Fjames-m-wilson-jr&amp;a=James+(Josh)+Wilson\" tabindex=\"0\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">James (Josh) Wilson</strong></a><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"> Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options</strong></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">If you suffered significant losses in </strong><a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=3661198299&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&amp;a=Aquestive+Therapeutics\" tabindex=\"0\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Aquestive Therapeutics</strong></a><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"> stock or options </strong>and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Josh Wilson directly </strong>at <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">877-247-4292 </strong>or <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">212-983-9330</strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"> (Ext. 1310)</strong>. </p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=906739697&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&amp;a=%5BYou+may+also+click+here+for+additional+information%5D\" tabindex=\"0\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">[You may also click here for additional information]</strong></a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span data-v-602de5d2=\"\">NEW YORK</span>, <span data-v-602de5d2=\"\">Feb. 28, 2026</span> /PRNewswire/ -- <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=2374974588&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2F&amp;a=Faruqi+%26+Faruqi%2C+LLP\" tabindex=\"0\">Faruqi &amp; Faruqi, LLP</a>, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (\"Aquestive\" or the \"Company\") (NASDAQ: AQST).</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://mma.prnewswire.com/media/2457438/Faruqi_Logo.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/2457438/Faruqi_Logo.jpg\"/></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Faruqi &amp; Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=2466615924&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2F&amp;a=www.faruqilaw.com\" tabindex=\"0\">www.faruqilaw.com</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) plunged approximately 40% intraday on Friday after the company disclosed that the U.S. Food and Drug Administration (FDA) identified deficiencies in its New Drug Application (NDA) for Anaphylm, its experimental sublingual film for the treatment of severe allergic reactions, including anaphylaxis. The FDA advised that the unidentified deficiencies currently prevent discussions of labeling and post-marketing requirements, raising concerns about the application's approvability ahead of the January 31, 2026, PDUFA action date.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">To learn more about the <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Aquestive Therapeutics</strong> investigation, go to <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=793030824&amp;u=https%3A%2F%2Fwww.faruqilaw.com%2FAQST&amp;a=www.faruqilaw.com%2FAQST\" tabindex=\"0\"><strong class=\"mdc-article-strong\" data-v-479a2324=\"\">www.faruqilaw.com/AQST</strong></a> or <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">call</strong> Faruqi &amp; Faruqi partner <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">Josh Wilson directly </strong>at <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">877-247-4292 </strong>or <strong class=\"mdc-article-strong\" data-v-479a2324=\"\">212-983-9330</strong><strong class=\"mdc-article-strong\" data-v-479a2324=\"\"> (Ext. 1310)</strong>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Follow us for updates on <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=2565505647&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffaruqi-%26-faruqi-llp%2F&amp;a=LinkedIn\" tabindex=\"0\">LinkedIn</a>, on <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=3768899423&amp;u=https%3A%2F%2Fx.com%2Ffaruqilaw&amp;a=X\" tabindex=\"0\">X</a>, or on <a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=1385065218&amp;u=https%3A%2F%2Fwww.facebook.com%2FFaruqiLaw%2F&amp;a=Facebook\" tabindex=\"0\">Facebook</a>.</p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">Attorney Advertising. The law firm responsible for this advertisement is Faruqi &amp; Faruqi, LLP (<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4629439-1&amp;h=1490028263&amp;u=http%3A%2F%2Fwww.faruqilaw.com%2F&amp;a=www.faruqilaw.com\" tabindex=\"0\">www.faruqilaw.com</a>). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.</p>\n<span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.html\" tabindex=\"0\">\n<span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img\" data-v-f0ef0696=\"\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://mma.prnewswire.com/media/2745617/Faruqi__Faruqi_LLP_James_Josh_Wilson.jpg\"/></picture></span>\n</a>\n</p>\n</span>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\"><span class=\"mdc-article-image\" data-v-f0ef0696=\"\"><picture class=\"mdc-responsive-image mdc-article-image__img mdc-article-image__img--12-width\" data-v-f0ef0696=\"\" style=\"width:12px;\"> <img alt=\"\" class=\"mdc-responsive-image__image\" src=\"https://edge.prnewswire.com/c/img/favicon.png?sn=NY97985&amp;sd=2026-02-28\"/></picture></span> View original content to download multimedia:<a class=\"mdc-link__mdc mdc-link--body__mdc\" href=\"https://www.prnewswire.com/news-releases/aqst-investor-notice-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-aquestive-therapeutics-302699973.html\" tabindex=\"0\">https://www.prnewswire.com/news-releases/aqst-investor-notice-faruqi--faruqi-llp-investigates-claims-on-behalf-of-investors-of-aquestive-therapeutics-302699973.html</a></p><p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">SOURCE Faruqi &amp; Faruqi, LLP</p></span>\n</div>",
            "pub_date": "2026-02-28 21:40:48",
            "link": "https://www.morningstar.com/news/pr-newswire/20260228ny97985/aqst-investor-notice-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-aquestive-therapeutics",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The week, FOBO - 'fear of becoming obsolete' because of AI - became real for workers and markets",
            "description": "<div class=\"mdc-article-body\">\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  By Weston Blasi and Andrew Keshner </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Massive jobs cuts at Block and a cataclysmic Citrini blog post stoked anxieties - but some CEOs and researchers are skeptical about doomsday scenarios </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"Fear of becoming obsolete\" has become an increasing concern for workers. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This past week, Block CEO Jack Dorsey announced that the parent company of Square and Cash App was cutting nearly half its employees - some 4,000 workers - because AI and \"intelligence tools have changed what it means to build and run a company.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     On Monday, Citrini Research put out a blog post laying out a hypothetical, cataclysmic near-future in which AI eliminates white-collar jobs, upending companies and entire industries. The 7,200-word essay from the independent research firm helped spark a selloff in software stocks that wiped out $200 billion in market value. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This felt like the week that \"FOBO\" - the \"fear of becoming obsolete\" - moved from being a theoretical discussion to having real-world implications. And new research offers a glimpse at the price people are willing to pay in order to manage those fears. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Almost two-thirds of workers across the world (63%) say they'd trade a 10% pay increase for a chance to improve their AI and digital skills, according to a new report from Mercer, a human-resources consulting firm. That detail is one part of a wider report showing how employers, investors and workers across the globe are trying to understand what AI's ascent means for their future plans. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Four in 10 workers say one of their biggest worries about their future work plans is job loss because of AI. That's up from two years ago, when 28% of workers felt that way, the report said. To be sure, workers acknowledge the ways AI is helping; 8 in 10 employees said AI has made them \"more productive and efficient at work.\" At the same time, 6 in 10 workers say company brass is underestimating AI's psychological toll on staff as it muscles in. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     There's a lot of truth in worker apprehension: 99% of executives polled said AI will result in some head-count reductions within two years. But there is also a lot of uncertainty over how, exactly, AI will impact jobs and work. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Speaking at an investor event this week, JPMorgan Chase (JPM) CEO Jamie Dimon said workers may think that using AI is saving them four hours a day, but it's not necessarily translating into four hours of added value for JPMorgan. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"We have an LLM model; 150,000 people use it every week,\" Dimon said. \"They think they're saving four hours a day. That's not in an NPV [net present value] - we don't see the four hours a day in terms of reduced head count like that.\" </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     And some analysts have argued that Block's (XYZ) decision to slash jobs was a way for the company to blame AI while correcting a reckless postpandemic hiring binge, helping to send its stock soaring. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Are AI fears grounded in a myth? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The new Mercer report reflects a \"growing sense of anxiety\" among workers, said Ravin Jesuthasan, who is the firm's global leader for transformation services. But he added that while AI will be able to perform certain tasks that workers traditionally handled, many companies are focused on redeveloping worker skills, instead of making deep cuts that would effectively turn staff salaries and training into a sunk cost. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Keith Spencer, career expert at job-search automation platform Sonara, told MarketWatch that while AI is speeding up daily tasks, it isn't fundamentally changing how the work gets done. And until it does, those time savings may not show up in revenue or margins. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"AI is largely being layered onto existing work rather than fundamentally redesigning workflows,\" Spencer said, noting that many professionals are using it to draft emails or presentations, summarize information, analyze data or automate repetitive administrative chores. \"Completing tasks faster doesn't automatically mean a company or team is suddenly producing more products or serving more customers,\" he noted, which would have a more noticeable impact on revenue. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Read also: CEOs say they won't add many jobs in 2026. Is a low-hire, low-fire labor market the new norm? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     In recently published research for the Harvard Business Review, authors Aruna Ranganathan and Xingqi Maggie Ye argued that it's a myth that AI will reduce employee workloads. Instead of shrinking their work, AI will lead to \"work intensification\" where employees use their newfound tools to tackle a broader scope of tasks, resulting in increased multitasking across the company. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     A temporary surge in productivity may occur, the authors said, but it can be unsustainable. Over the long term, such practices can lead to \"workload creep,\" cognitive fatigue and a decline in quality of decision-making. In the long term, AI tools meant to save time can make workers feel busier and more stretched because they're taking on more tasks. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Preventing these AI-related burnout issues can be tough, but possible. Ranganathan and Ye suggest companies establish a formal \"AI practice,\" where expected interruptions can occur at work. Those can take the form of intentional pauses to assess workflow and sequencing work to reduce AI fragmentation. Having practices in place to ground AI work tasks with human thinking can protect creativity and ensure long-term sustainability </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     For now, some 12% of employees say they are using AI daily at their jobs, according to a Gallup Workforce survey of more than 22,000 U.S. workers, and 26% say they use it multiple times a week - up from 10% and 23%, respectively, year over year. And some tech giants like Amazon.com (AMZN), Google (GOOGL) (GOOG) and Meta Platforms (META) have rolled out AI tools that their workers are now required to incorporate into their daily tasks. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Entry-level workers are in a pinch - but for how long? </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Workers may have to recalibrate their skills looking ahead. But in a sense, they already have a leg up because they at least have a job. Entry-level work has long had its difficulties, but it's in sharp focus now as AI increases its office presence. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     A Federal Reserve Bank of Dallas report this week noted there are jobs requiring black-and-white textbook knowledge, and there are jobs requiring knowledge from experience. It's essentially the difference between book smarts and street smarts. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Street smarts may hold the upper hand for now. Early data show wages are increasing for AI-exposed jobs that \"place a high value on a worker's tacit knowledge and experience,\" wrote J. Scott Davis, an assistant vice president in the Dallas Fed's research department. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     The challenge is finding ways to give new workers valuable experience when AI is increasingly handling the textbook work that used to be meant for entry-level employees, Davis said. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Businesses may determine it's not an effective move in the short run to keep giving new employees textbook grunt work as they slowly build their experience. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     \"Of course, leaving new employees off the job ladder is not sustainable in the long run. In the long run, AI adoption will require rethinking how entry-level employees gain experience on the job,\" Davis wrote. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Job-market conditions for recent college graduates deteriorated at the end of last year, according to the Federal Reserve Bank of New York. The fourth-quarter jobless rate for new grads rose to 5.7%, from 5.3%, in the third quarter, while the underemployment rate climbed to its highest point since 2020. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     Underemployment counts as working in a job that generally does not require a college degree, researchers said. </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     -Weston Blasi -Andrew Keshner </p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. </p>\n<pre class=\"mdc-article-pre\" data-v-370ea3ac=\"\"></pre>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  (END) Dow Jones Newswires</p>\n<p class=\"mdc-article-paragraph\" data-v-602de5d2=\"\">\n  02-28-26 0830ET</p>\n\nCopyright (c) 2026 Dow Jones &amp; Company, Inc.</div>",
            "pub_date": "2026-02-28 21:40:47",
            "link": "https://www.morningstar.com/news/marketwatch/20260228146/the-week-fobo-fear-of-becoming-obsolete-because-of-ai-became-real-for-workers-and-markets",
            "source": "morningstar",
            "kind": 1,
            "language": "en"
        }
    ]
}